AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18271227 — intervention group
Group type: COMPARATOR
Intervention: Saline acupoint injection
Number of subjects: 150
Study 18271227 — intervention group
Group type: COMPARATOR
Intervention: Huichun Ruyi capsules
Number of subjects: 150
Study 16302325 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin/zinc gel applied once daily
Number of subjects: 246
Study 16302325 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin/zinc gel applied twice daily
Number of subjects: 246
Study 16302325 — intervention group
Group type: COMPARATOR
Intervention: 1% clindamycin lotion applied twice daily
Number of subjects: 246
Study 12044272 — intervention group
Group type: EXPERIMENTAL
Intervention: VAQTA, TyphimVi, and YF‐VAX on day 0 and VAQTA at week 24 (Group 1)
Number of subjects: 240
Study 12044272 — intervention group
Group type: EXPERIMENTAL
Intervention: TyphimVi and YF‐VAX on day 0 and an optional dose of VAQTA 1 month later (Group 2)
Number of subjects: 240
Study 12044272 — intervention group
Group type: EXPERIMENTAL
Intervention: VAQTA at day 0 and week 24 (Group 3)
Number of subjects: 240
Study 9860240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pseudoallergen diet for 3 weeks followed by provocation with food rich in pseudoallergens
Number of subjects: 16
Study 9860240 — intervention group
Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenges
Number of subjects: 16
Study 7617493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60
Study 7617493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 60
Study 7617493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2508161 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg orally administered diazepam
Number of subjects: 24
Study 2508161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 202346 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 25 mg/night for three consecutive nights
Number of subjects: 14
Study 202346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31699704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/day)
Number of subjects: 784
Study 31699704 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA (1 g/day)
Number of subjects: 784
Study 31699704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study 29976582 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase treatment decision based on NIHSS scores
Number of subjects: 156
Study 29976582 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint model analysis
Number of subjects: 156
Study 29976582 — intervention group
Group type: EXPERIMENTAL
Intervention: Model accounting for all possible interactions
Number of subjects: 156
Study 29976582 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing treatment decisions
Number of subjects: 156
Study 27351218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 92
Study 27351218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Tie2 + Ca125
Number of subjects: 92
Study 24757227 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 16
Study 22892110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg twice a day for 5 consecutive days
Number of subjects: 0
Study 22892110 — intervention group
Group type: COMPARATOR
Intervention: Placebo 100 mg twice a day for 5 consecutive days
Number of subjects: 0
Study 22892110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 0
Study 22892110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20706917 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Control Treatment for Adolescents (PCT‐A)
Number of subjects: 26
Study 20706917 — intervention group
Group type: COMPARATOR
Intervention: Self‐monitoring control group
Number of subjects: 26
Study 17954368 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril alone for 1 week
Number of subjects: 21
Study 17954368 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine alone for 6 weeks
Number of subjects: 21
Study 17954368 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril + Amlodipine for 6 weeks
Number of subjects: 21
Study 17954368 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine alone after discontinuation of Quinapril for 6 weeks
Number of subjects: 21
Study 17954368 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle sympathetic nerve activity (MSNA)
Number of subjects: 21
Study 17954368 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II levels
Number of subjects: 21
Study 16135167 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (352 mg per day)
Number of subjects: 30
Study 16135167 — intervention group
Group type: COMPARATOR
Intervention: Bromhexine hydrochloride (4 mg per day)
Number of subjects: 30
Study 12371046 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls and mailings once every month for 6 months
Number of subjects: 50
Study 12371046 — intervention group
Group type: COMPARATOR
Intervention: No intervention phone calls or mailings (control group)
Number of subjects: 50
Study 10466282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum practices that are demonstrably safe and useful
Number of subjects: 0
Study 10466282 — intervention group
Group type: COMPARATOR
Intervention: Intrapartum practices with trade-offs between beneficial and adverse effects
Number of subjects: 0
Study 7475592 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint consultation sessions of GPs and orthopaedic surgeons (n = 144)
Number of subjects: 272
Study 7475592 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (n = 128)
Number of subjects: 272
Study 2248816 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg
Number of subjects: 50
Study 2248816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7016484 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin plus magnesium sulfate
Number of subjects: 173
Study 7016484 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 173
Study 30641129 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal myectomy with subvalvular intervention
Number of subjects: 80
Study 30641129 — intervention group
Group type: COMPARATOR
Intervention: Septal myectomy without subvalvular intervention
Number of subjects: 80
Study 27808528 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant coping style
Number of subjects: 264
Study 27808528 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-related distress
Number of subjects: 264
Study 27808528 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management behaviors
Number of subjects: 264
Study 27808528 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control (hemoglobin A1c)
Number of subjects: 264
Study 26718674 — intervention group
Group type: EXPERIMENTAL
Intervention: Substrate-based ablation
Number of subjects: 118
Study 26718674 — intervention group
Group type: COMPARATOR
Intervention: Clinical VT ablation
Number of subjects: 118
Study 26718674 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined incidence of rehospitalization and mortality
Number of subjects: 118
Study 26718674 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural complications
Number of subjects: 118
Study 23278355 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (breath alcohol concentration 50 mg/dl)
Number of subjects: 32
Study 23278355 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 32
Study 21933534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated group
Number of subjects: 14883
Study 19156155 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCT
Number of subjects: 112
Study 19156155 — intervention group
Group type: COMPARATOR
Intervention: LCT
Number of subjects: 112
Study 17158146 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural strategies delivered over individual structured MCH consultations
Number of subjects: 328
Study 17158146 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study 14992558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats-containing gluten-free diet (50 g daily)
Number of subjects: 39
Study 14992558 — intervention group
Group type: COMPARATOR
Intervention: Traditional gluten-free diet (without oats)
Number of subjects: 39
Study 10584476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day for 5 days, tapered progressively)
Number of subjects: 29
Study 10584476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 29
Study 10584476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9097714 — intervention group
Group type: EXPERIMENTAL
Intervention: FSGS
Number of subjects: 30
Study 9097714 — intervention group
Group type: EXPERIMENTAL
Intervention: MCD
Number of subjects: 30
Study 9097714 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 30
Study 1827040 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis
Number of subjects: 123
Study 1827040 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated Dacron prosthesis
Number of subjects: 123
Study 1827040 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis (aneurysmal disease)
Number of subjects: 123
Study 1827040 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated Dacron prosthesis (aneurysmal disease)
Number of subjects: 123
Study 1827040 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis (occlusive disease)
Number of subjects: 123
Study 1827040 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated Dacron prosthesis (occlusive disease)
Number of subjects: 123
Study 6949237 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 51
Study 6949237 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 51
Study 31318392 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab combination therapy (1500 mg durvalumab every 4 weeks and 75 mg tremelimumab every 4 weeks for 4 cycles, followed by durvalumab monotherapy for up to 12 months)
Number of subjects: 65
Study 31318392 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab monotherapy (1500 mg every 4 weeks for up to 12 months)
Number of subjects: 65
Study 29334436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stabilized stannous fluoride dentifrice (Crest® Pro‐Health™)
Number of subjects: 200
Study 29334436 — intervention group
Group type: COMPARATOR
Intervention: 0.30% triclosan dentifrice (Colgate® Total®)
Number of subjects: 200
Study 24999214 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% cocaine (n = 39)
Number of subjects: 79
Study 24999214 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cocaine (n = 40)
Number of subjects: 79
Study 22684565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 22684565 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 20693265 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage memory loss support group (ESML)
Number of subjects: 142
Study 20693265 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 142
Study 17545007 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 0
Study 17545007 — intervention group
Group type: COMPARATOR
Intervention: No induction therapy
Number of subjects: 0
Study 15716702 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day enalapril (ACE inhibitor)
Number of subjects: 17
Study 15716702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12059936 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT/gutta-percha
Number of subjects: 66
Study 12059936 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT without gutta-percha
Number of subjects: 66
Study 12059936 — intervention group
Group type: COMPARATOR
Intervention: Control (lateral condensation, McSpadden technique)
Number of subjects: 66
Study 10530414 — intervention group
Group type: EXPERIMENTAL
Intervention: Roquinimex (Linomide), 0.2 mg/kg body weight, twice weekly for 2 years
Number of subjects: 13
Study 10530414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8543206 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac-sodium 0.1% eye drops
Number of subjects: 41
Study 8543206 — intervention group
Group type: COMPARATOR
Intervention: placebo (vehicle)
Number of subjects: 41
Study 2031798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium diatrizoate (ionic monomer) at 150 mg I/ml (726 mosmol/kg)
Number of subjects: 0
Study 2031798 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (non-ionic monomer) diluted to the same iodine concentration but at 324.3 mosmol/kg
Number of subjects: 0
Study 6138593 — intervention group
Group type: EXPERIMENTAL
Intervention: RA 27/3
Number of subjects: 100
Study 6138593 — intervention group
Group type: COMPARATOR
Intervention: Cendehill
Number of subjects: 100
Study 30919942 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 83985
Study 30919942 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 83985
Study 29161417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU oral weekly for 12 weeks)
Number of subjects: 41
Study 29161417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral weekly for 12 weeks)
Number of subjects: 41
Study 26879279 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 334 70 mg
Number of subjects: 483
Study 26879279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 26879279 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 334 7 mg
Number of subjects: 483
Study 26879279 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 334 21 mg
Number of subjects: 483
Study 24854605 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE kV (automated attenuation-based tube potential optimization mode)
Number of subjects: 89
Study 24854605 — intervention group
Group type: COMPARATOR
Intervention: 120 kV
Number of subjects: 89
Study 22339125 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) 600/100 mg bid
Number of subjects: 595
Study 22339125 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 400/100 mg bid
Number of subjects: 595
Study 20540443 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5-40 mg) and Flumazenil (0.36 mg)
Number of subjects: 6
Study 20540443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the placebo phase)
Number of subjects: 6
Study 20540443 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.36 mg)
Number of subjects: 6
Study 17454203 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17560289 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 20479
Study 17560289 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 20479
Study 14977992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterial purified protein derivatives (PPDs)
Number of subjects: 2
Study 14977992 — intervention group
Group type: COMPARATOR
Intervention: Control group (UK subjects)
Number of subjects: 2
Study 10623956 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (3 times a week for 12 weeks) targeting muscle force, endurance, balance, and flexibility
Number of subjects: 45
Study 10623956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 45
Study 9366455 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (bupivacaine)
Number of subjects: 40
Study 9366455 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (isoflurane and nitrous oxide)
Number of subjects: 40
Study 1483797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg slow release every 8 hours)
Number of subjects: 17
Study 1483797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1483797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 17
Study 6364778 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy including cyclophosphamide, imidazolecarboxamide, and vincristine given in 5-day pulses each month for 12 courses.
Number of subjects: 133
Study 6364778 — intervention group
Group type: COMPARATOR
Intervention: Multiagent chemotherapy (as prescribed).
Number of subjects: 133
Study 6364778 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment regimen from study CCG 011 (no chemotherapy or oral CPM).
Number of subjects: 133
Study 30935469 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective dorsal neurectomy (SDN) in group 2a
Number of subjects: 142
Study 30935469 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2b)
Number of subjects: 142
Study 30935469 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of dorsal penile nerve branches
Number of subjects: 142
Study 30935469 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 142
Study 29961772 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-Guided Biliary Drainage (EUS-BD)
Number of subjects: 125
Study 29961772 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 125
Study 27802843 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Action Programme (WAP)
Number of subjects: 330
Study 27802843 — intervention group
Group type: COMPARATOR
Intervention: Nurse intervention (best usual care)
Number of subjects: 330
Study 24807502 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet healthcare education and symptom flares consultation through short message service
Number of subjects: 80
Study 24807502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 80
Study 22683137 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily
Number of subjects: 1029
Study 22683137 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride once daily
Number of subjects: 1029
Study 19055510 — intervention group
Group type: EXPERIMENTAL
Intervention: Queckenstedt's test (Q-test)
Number of subjects: 39
Study 19055510 — intervention group
Group type: COMPARATOR
Intervention: Sham test
Number of subjects: 39
Study 18063177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tunnel position (2 o'clock)
Number of subjects: 60
Study 18063177 — intervention group
Group type: COMPARATOR
Intervention: High tunnel position (1 o'clock)
Number of subjects: 60
Study 15841092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (3 x 10^10 CFU, two capsules, three times a day for 6 weeks)
Number of subjects: 80
Study 15841092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules, three times a day for 6 weeks)
Number of subjects: 80
Study 12469331 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole
Number of subjects: 10
Study 12469331 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg albendazole
Number of subjects: 10
Study 12469331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg albendazole
Number of subjects: 10
Study 9585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 1305
Study 9585394 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide
Number of subjects: 1305
Study 9585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose > or = 10.0 mmol/l
Number of subjects: 1305
Study 9585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose > or = 7.8 mmol/l to < 10.0 mmol/l
Number of subjects: 1305
Study 9585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose < 7.8 mmol/l
Number of subjects: 1305
Study 9585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese subjects (BMI < 30 kg/m²)
Number of subjects: 1305
Study 9585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > or = 30 kg/m²)
Number of subjects: 1305
Study 9585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower beta-cell function
Number of subjects: 1305
Study 7805822 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterloo Smoking Prevention Program 1, adapted
Number of subjects: 792
Study 7805822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 792
Study 2817307 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (terbutaline inhalation)
Number of subjects: 21
Study 2817307 — intervention group
Group type: COMPARATOR
Intervention: Nebuhaler (terbutaline inhalation)
Number of subjects: 21
Study 51664 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid cream
Number of subjects: 100
Study 51664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31492999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycinnamic acid amides (HCAA) profiling using mass spectrometry-multiple reaction monitoring (UPLC-MRM)
Number of subjects: 0
Study 31492999 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycinnamic acid esters (HCAE) profiling using ultra-performance liquid chromatography-photodiode array detection (UPLC-PDA)
Number of subjects: 0
Study 31492999 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial least square discriminant analysis (PLS-DA) applied to both HCAE and HCAA datasets
Number of subjects: 0
Study 31492999 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of supplement samples
Number of subjects: 0
Study 27879193 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumagen® 370 mg tablet
Number of subjects: 0
Study 27879193 — intervention group
Group type: COMPARATOR
Intervention: Somalgen® 370 mg tablet
Number of subjects: 0
Study 25597371 — intervention group
Group type: EXPERIMENTAL
Intervention: gatifloxacin 0.3%
Number of subjects: 40
Study 25597371 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin 0.5%
Number of subjects: 40